As of 2025-05-17, the Intrinsic Value of Beijing Chunlizhengda Medical Instruments Co Ltd (1858.HK) is 22.04 HKD. This 1858.HK valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 9.51 HKD, the upside of Beijing Chunlizhengda Medical Instruments Co Ltd is 131.80%.
The range of the Intrinsic Value is 18.49 - 27.61 HKD
Based on its market price of 9.51 HKD and our intrinsic valuation, Beijing Chunlizhengda Medical Instruments Co Ltd (1858.HK) is undervalued by 131.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 18.49 - 27.61 | 22.04 | 131.8% |
| DCF (Growth 10y) | 32.56 - 50.72 | 39.63 | 316.7% |
| DCF (EBITDA 5y) | 72.69 - 108.46 | 91.14 | 858.4% |
| DCF (EBITDA 10y) | 94.24 - 154.48 | 123.44 | 1198.0% |
| Fair Value | 5.19 - 5.19 | 5.19 | -45.47% |
| P/E | 19.29 - 47.36 | 35.21 | 270.2% |
| EV/EBITDA | 20.05 - 60.92 | 38.97 | 309.8% |
| EPV | 6.72 - 8.51 | 7.62 | -19.9% |
| DDM - Stable | 8.22 - 16.60 | 12.41 | 30.5% |
| DDM - Multi | 17.86 - 28.88 | 22.14 | 132.8% |
| Market Cap (mil) | 3,654.50 |
| Beta | -0.20 |
| Outstanding shares (mil) | 384.28 |
| Enterprise Value (mil) | 3,077.14 |
| Market risk premium | 5.81% |
| Cost of Equity | 8.73% |
| Cost of Debt | 5.00% |
| WACC | 8.72% |